VMDNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
VIEMED HEALTHCARE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$9.59+0.11 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $394.40M
- P/E (TTM)
- 26.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
57.5%−3.5 pts over 5 years
Operating margin
8.5%−11.9 pts over 5 years
Net margin
5.5%−18.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +20.5% | +24.9% | +15.5% | – | |
| Gross profit | +16.7% | +22.4% | +14.2% | – | |
| Operating income | +28.2% | +40.6% | -3.0% | – | |
| Net income | +32.6% | +33.9% | -13.9% | – | |
| EPS, diluted | +32.1% | +32.2% | -13.9% | – | |
| Free cash flow | +805.2% | +35.0% | -11.6% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 50.3% | 10.9% | |
| Return on assets | – | 32.3% | 7.9% | |
| Current ratio | – | 2.05 | 1.18 | |
| Debt to equity | – | 0.09 | 0.09 | |
| Net debt to EBITDA | – | – | -0.02× | |
| Inventory turnover | – | 27.9× | 24.5× | |
| Capex to revenue | – | 9.9% | 14.8% | |
| Diluted shares | – | 41M | 41M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Viemed Healthcare generated $186.46M from operations and spent $169.28M on capital expenditure, dividends and share buybacks. 87% of that went back into the business.
Generated
$186.46M
Used
$169.28M
Capital expenditure$146.49M87%Dividends$00%Share buybacks$22.79M13%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin5.5%
×Asset turnover1.44×
×Equity multiplier1.38×
=Return on equity, FY202510.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 5.5% | 1.44× | 1.38× | 10.9% |
| FY2024 | 5.0% | 1.35× | 1.35× | 9.2% |
| FY2023 | 5.6% | 1.35× | 1.29× | 9.7% |
| FY2022 | 4.5% | 1.18× | 1.22× | 6.5% |
| FY2021 | 7.8% | 1.02× | 1.31× | 10.3% |
| FY2020 | 24.0% | 1.35× | 1.56× | 50.3% |
| FY2019 | 10.6% | 1.18× | 1.79× | 22.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$14.93M
- Cash generatingOperating cash flow above zero$51.92M
- Return on assets improvedROA up on the prior year7.3% → 8.4%
- Earnings backed by cashOperating cash flow above net income$51.92M vs $14.93M
- Less leverageLong-term debt to assets fell2.0% → 5.7%
- Better liquidityCurrent ratio rose1.42 → 1.18
- No dilutionShare count did not rise41M → 41M
- Gross margin improvedGross margin up on the prior year59.40% → 57.52%
- More efficientAsset turnover rose1.45 → 1.53